Gap between guidelines and practice: Attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events including Physicians' Experience and Evaluation)

European Journal of Preventive Cardiology

Volumn 13, Issue 5, 2006, Pages 776-783

  Assmann, Gerd ^a   Benecke, Heike ^b   Neiss, Albrecht ^c   Cullen, Paul ^a   Schulte, Helmut ^a   Bestehorn, Kurt ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

coronary heart disease; coronary risk prediction; hypercholesterolemia; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DISEASE REGISTRY; DRUG EFFECT; DRUG EFFICACY; EDUCATION PROGRAM; FEMALE; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PRIVATE PRACTICE; RISK ASSESSMENT; SECONDARY PREVENTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33749030970     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000189805.76482.6e     Document Type: Article

References (26)

1. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310–315.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
5. Wood D, De Backer G, Faergemann O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434–1503.
6. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease [online publication]. athero.org; 2003. http://www.athero.org. [Accessed].
7. EUROASPIRE: A European Society of Cardiology survey for the potential for secondary prevention of coronary heart disease in nine European countries. Atherosclerosis 1997; 130: 148.
8. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. European Action on Secondary Prevention Through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569–1592.
9. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
10. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.
11. Fornengo P, Bruno G, De Salvia A, Acari R, Pisu E, Pagano G. Low adherence of General Practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000; 13: 263–268.
12. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith AC. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 2001; 21: 818–827.
13. Baessler A, Fischer M, Hengstenberg C, Mayer B, Holmer S, Hubauer U, et al Guideline-adapted statin therapy improves outcome in patients with myocardial infarction Circulation 2002; 106 (Suppl):3683.
14. Durrington P. The human and economic costs of undertreatment with statins. Int J Clin Pract 2002; 56: 357–368.
15. Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, et al Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group [in German]. Z Kardiol 2001; 90: 148–149.
16. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004; 173: 381–391.
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
19. Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge Int J Cardiol 2000; 74(Suppl 1):S23–S28.
20. Devroey D, de Swaef N, Coigniez P, Vandevoorde J, Kartounian J, Betz W. Results from a cardiovascular prevention campaign in persons aged 45–64 years. Int J Clin Pract 2003; 57: 430–434.
21. März W, Wollschläger H, Klein G, Neiß A, Wehling M. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol 1999; 84: 7–13.
22. Ruof J, Klein G, März W, Wollschläger H, Neiss A, Wehling M. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002; 35: 48–53.
23. Frolkis JP, Pearce GL, Nambi V, Minor S, Sprecher DL. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med 2002; 113: 625–629.
24. Broeders N, Knoop C, Abramowicz D. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 2020–2021.
25. Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. Atherosclerosis 2000; 149: 199–205.
26. Jönsson B. Economics of drug treatment: for which patients is it cost effective to lower cholesterol? Lancet 2001; 358: 1251–1256.